March 28 U.S. health regulators denied approval
to A.P. Pharma Inc's drug for treating
chemotherapy-induced nausea and vomiting, and asked for
additional analysis of existing late-stage data on the drug.
The U.S. Food and Drug Administration also asked for a study
that can test the usability of the drug's syringe system.
The agency had earlier rejected the approval of the drug,
APF530, in March 2010, citing concerns about its two-syringe
administration system and deficiencies in the company's contract
A.P. Pharma resubmitted its application in September last
year after switching to a single-syringe system and conducting
additional metabolism studies as required by the FDA.